RVXCF
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.01 | $0 | -$975,301 |
| 2025 Q4 | 0.00 | $0 | -$1M |
| 2025 Q3 | -0.00 | $0 | -$913,000 |
| 2025 Q2 | -0.01 | $0 | -$1M |
| 2025 Q1 | -0.02 | $0 | -$1M |
| 2024 Q4 | 0.00 | $0 | -$1M |
| 2023 Q3 | -0.02 | $0 | $57,000 |
| 2023 Q2 | -0.01 | $0 | $122 |